This will be very interesting and helpful for understanding the role of both FLT3 and CEBPΑ aberrations in leukaemia development using the clinical outcomes of AML patients carrying FLT3 and CEBPΑdm co-occurrence mutations treated with FLT3i therapies. The gene discussed is CEBPA; the disease is acute myeloid leukemia.